Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Phase 2 Completed 10 enrolled HonorHealth Research Institute Bayer · collab Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.

Timeline

Start: 2021-10-28
Primary completion: 2024-11-08
Completion: 2024-12-13

Outcome

Missed primary endpoint

paper Disease control rate was 0%. PMID 41766762 ↗

paper The combination of vemurafenib and sorafenib in KRAS-mutated refractory pancreatic cancer did not yield disease control in this pilot phase II study. PMID 41766762 ↗

Publications

Khawaja MR, Jameson G, Cridebring D, Shannon P, Han H, Moore J, Von Hoff D, Posner RG, Hlavacek WS, Kolch W, Kholodenko BN, Rukhlenko OS, Roe DJ, Wertheim BC, Borazanci E. Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. J Immunother Precis Oncol. 2026 Feb 10;9(1):17-24. doi: 10.36401/JIPO-25-20. eCollection 2026 Feb.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	200 mg	Oral
Subject	Vemurafenib	Small molecule	480 mg	Oral